Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Abstract Aims/Introduction Although the efficacy of teneligliptin, a highly selective dipeptidyl peptidase‐4 inhibitor, has been amply studied for the treatment of type 2 diabetes, no clinical trials of teneligliptin have been carried out in China. We evaluated the efficacy and safety of teneliglipt...

Full description

Bibliographic Details
Main Authors: Linong Ji, Jianhua Ma, Weiping Lu, Jingdong Liu, Jiao’e Zeng, Jialin Yang, Wei Li, Xiuzhen Zhang, Xinhua Xiao, Gen Takayanagi, Yi Wang
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Journal of Diabetes Investigation
Subjects:
China
Dipeptidyl peptidase‐4 inhibitors
Type 2 diabetes mellitus
Online Access:https://doi.org/10.1111/jdi.13389

Internet

https://doi.org/10.1111/jdi.13389

Similar Items